For the pharmaceutical sector, 2009 was a year when Indian manufacturing capabilities took centre stage. For the first time, global pharmaceutical giants like Pfizer and GlaxoSmithKline (GSK) came shopping for Indian manufacturers. Pharmaquest.biz recaps some of biggest inbound pharma deals this year.
Few outside the recently developed township of Baddi in Himachal Pradesh will know Arun Rawat or his drug manufacturing company Kanha Biogenetic Laboratories. But this first-generation entrepreneur, who ventured into the drug-making business just five years ago, produces medicines for such majors as Wockhardt, Ajanta Pharma and Ind-Swift, to name a few.
Yet another year has also gone by. But the issues related to pharma and health sectors remain mostly unresolved, thanks to the lackadaisical manner in which the government looks at these issues. Several crucial files regarding policies and regulations related to these sectors are still stuck at various government departments with no sign of immediate disposal. The only silver lining on the otherwise gloomy horizon was the introduction of 'Transplantation of Human Organs Act, 1994' in Parliament at the fag end of the last session of Parliament.
Painkillers may help relieve pain, but as with most things, too much of the drugs is bad for health. Some learn it the hard way.
The Hyderabad-based Dr Reddy's Labs is planning to launch new generic drugs in various therapeutic segments to give a push to its domestic operations and get back to among the top ten firms in the country.
Many shifting focus to emerging economies in struggle to stay afloatMajor Japanese pharmaceutical makers are expediting projects to construct plants and expand sales channels in emerging economies, such as China and India.
Drug maker scouting for Indian companies specializing in therapy segments such as nephrology and urology
Glenmark Pharmaceuticals is looking to out-license at least one molecule in fiscal 2010, probably Melogliptin.
From the national independence in the late 40s, the Indian companies have acted in two ways – either forging partnership with a globally acclaimed conglomerate or remaining as the raw material supplier to any multinational corporation. But now, it seems, those days are gone and Indian companies are desirous to capitalize on the changing worldwide fiscal scenario and Dr. Reddy’s Laboratories, Indian pharma major, is set to be the vanguard. How?
Its pharma's turn to take center stage. Here's a look back at the highs and lows of what happened in 2009.
Japanese pharma major Eisai Co, said its Visakhapatnam facility will emerge as the global hub for R&D, formulations and active pharmaceutical ingredients (API) manufacturing in the years to follow.
French drug manufacturing giant Sanofi-Aventis is stepping up its presence in the nonprescription drug market in the United States and Europe.
Leading Indian drug majors, such as Ranbaxy Laboratories, Dr Reddy’s Laboratories, Piramal Healthcare and Wockhardt, are in-licensing popular products from overseas drug makers to boost their domestic sales.
The swine flu pandemic forced pharma groups to develop vaccines as quickly as possible but the market for such disease-resistant products has been booming for years.
Big Pharma made this a big year for Indian drugmakers. As multinational companies sought ways to cut costs and grow revenues, they ramped up their outsourcing programs and partnerships–and that has helped push sales growth past 20 percent for India's leading drugmakers, such as Ranbaxy Laboratories, Cipla, Dr Reddy's Laboratories, and Aurobindo Pharma, according to the report.
DR REDDY’S Laboratories plans to buy brands in Russia and introduce new products in India as it plans to scale up businesses in key emerging markets, a top company executive said.
After East Europe and Mexico, Daiichi Sankyo, which bought out Ranbaxy Labs Ltd last year, is all set to leverage the latter’s marketing and distribution strength in six countries of Africa. This is the third instance in the last four months where Ranbaxy is helping Daiichi create a presence and consolidate its position in new emerging markets.
OncoGenex Pharmaceuticals Inc signed a licensing agreement with Israel's Teva Pharmaceutical Industries Ltd for its cancer therapy for an upfront payment of $60 million, but OncoGenex shares got hammered as investors expected a better deal.
Seattle Genetics just scored a potentially big licensing deal with Big Pharma. The Bothell biotech company announced a collaboration agreement with GlaxoSmithKline that will give Glaxo rights to use its antibody-drug conjugate technology.
The market has recently seen the re-rating of small companies in the FMCG and pharma sectors. FMCG players Dabur India and Emami witnessed the stocks of their recently-acquired companies, Fem Care Pharma and Zandu Pharma getting re-rated. Similarly, pharma companies, Cadila Care and Elder Pharma, have seen a lot of price action in the stocks of Zydus Wellness and Elder Health Care, respectively which were hived-off into independent companies respectively.